Deletions of the long (q) arm of chromosome 5 [del(5q)]occur in patients with myelodysplastic syndromes (MDS) including, but not limited to, those who meet the WHO definition of the 5q− syndrome.

This study builds on previous evidence for lenalidomide-induced selective advantage for TP53-mutant clones. MDS with del(5q) is a specific type of MDS that does not have excess blasts and is ...

Lenalidomide has proven efficacy and safety and has been shown to reduce transfusion requirements and reverse cytogenetic abnormalities in lower-risk myelodysplastic syndromes (MDS). However, ...

Dr Haumschild leads a discussion surrounding the latest advancements in treatment algorithms for myelodysplastic syndrome. The discussion centered on diverse treatment strategies for myelodysplastic ...

Patients with lower risk myelodysplastic syndrome may now receive imetelstat — despite it not being FDA-approved. Patients with lower risk myelodysplastic syndrome (MDS) — a type of cancer that starts ...